Physician profile
George A Wooming
NPI 1760457733
$23,607.54
in general payments reported to CMS, 2019-2025
37 companies · $3,094 in 2025
The $3,094 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,063 · 2020: $6,103 · 2021: $1,698 · 2022: $3,599 · 2023: $3,648 · 2024: $2,404 · 2025: $3,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,153 · Consulting Fee: $1,875 · Education: $113 · Travel and Lodging: $3.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,153.44 |
| Consulting Fee | $1,875.00 |
| Education | $113.17 |
| Travel and Lodging | $3.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,680.58 | 2019-2025 | |
| Abbvie INC. | $2,436.23 | 2019-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $1,657.73 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Epi Health, LLC | $1,540.60 | 2020-2022 | |
| Arcutis Biotherapeutics, INC. | $1,391.11 | 2023-2024 | Zoryve |
| Genzyme Corporation | $990.81 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $979.94 | 2020-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $803.32 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $700.94 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $603.23 | 2019-2025 | Tremfya |
| Incyte Corporation | $570.42 | 2021-2025 | Opzelura |
| Amgen INC. | $518.62 | 2020-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $506.68 | 2019-2025 | Targretin, Arazlo, Jublia |
| Mayne Pharma Commercial LLC | $445.00 | 2019-2024 | |
| Leo Pharma INC. | $443.02 | 2019-2025 | Adbry, Anzupgo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $427.41 | 2022-2025 | Sotyktu |
| Ucb, INC. | $417.02 | 2023-2025 | Bimzelx, Cimzia |
| Almirall LLC | $401.88 | 2019-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $373.36 | 2023-2024 | Vtama |
| Journey Medical Corporation | $298.23 | 2020-2025 | |
| Encore Dermatology INC. | $270.62 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $255.31 | 2020-2021 | |
| Sandoz INC. | $129.66 | 2019 | |
| Biofrontera INC. | $114.43 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Prugen, INC. Pharmaceuticals | $104.98 | 2019-2020 | |
| Organon LLC | $89.93 | 2025 | Vtama |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $77.43 | 2020-2023 | |
| Dermira, INC. | $58.30 | 2020-2021 | |
| Revance Therapeutics, INC. | $49.31 | 2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $40.18 | 2019 | |
| Glenmark Therapeutics INC. | $38.00 | 2019 | |
| Promius Pharma LLC | $33.29 | 2019 | |
| Sebela Pharmaceuticals INC. | $23.50 | 2019-2021 | |
| Allergan, INC. | $22.08 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.22 | 2025 | Nuzyra |
| Aclaris Therapeutics, INC. | $16.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Wooming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.